Edwards’ Peripheral Artery Growth-Factor Data Pooled By NIH’s Lederman
This article was originally published in The Pink Sheet Daily
Executive Summary
Intermittent claudication endpoint in Edwards/Sangamo gene-therapy compound study promoted by National Heart, Lung & Blood Institute principal investigator Lederman at Transcatheter Cardiovascular Therapeutics conference.
You may also be interested in...
Part D Enrollment Deadline Approaches With Fewer Than 6 Mil. Eligibles Still Unenrolled
The federal government is on the verge of ensuring that 90% of Medicare-eligible people receive prescription drug coverage, HHS Secretary Leavitt said.
GSK Takes Cue From Schering Patient Assistance Program, Seeks Opinion From OIG
HHS Office of Inspector General will decide whether GlaxoSmithKline can donate medicines to Part D-enrolled patients.
CAP Median Bid Prices, Physician Indifference Likely Contributed To Vendors Spurning Contracts
BioScrip will be the only provider of Medicare Part B-covered drugs through the competitive acquisition program for three years.